Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
Tóm tắt
Immune-regulated pathways influence multiple aspects of cancer development. In this article we demonstrate that both macrophage abundance and T-cell abundance in breast cancer represent prognostic indicators for recurrence-free and overall survival. We provide evidence that response to chemotherapy is in part regulated by these leukocytes; cytotoxic therapies induce mammary epithelial cells to produce monocyte/macrophage recruitment factors, including colony stimulating factor 1 (CSF1) and interleukin-34, which together enhance CSF1 receptor (CSF1R)–dependent macrophage infiltration. Blockade of macrophage recruitment with CSF1R-signaling antagonists, in combination with paclitaxel, improved survival of mammary tumor–bearing mice by slowing primary tumor development and reducing pulmonary metastasis. These improved aspects of mammary carcinogenesis were accompanied by decreased vessel density and appearance of antitumor immune programs fostering tumor suppression in a CD8+ T-cell–dependent manner. These data provide a rationale for targeting macrophage recruitment/response pathways, notably CSF1R, in combination with cytotoxic therapy, and identification of a breast cancer population likely to benefit from this novel therapeutic approach.
Significance: These findings reveal that response to chemotherapy is in part regulated by the tumor immune microenvironment and that common cytotoxic drugs induce neoplastic cells to produce monocyte/macrophage recruitment factors, which in turn enhance macrophage infiltration into mammary adenocarcinomas. Blockade of pathways mediating macrophage recruitment, in combination with chemotherapy, significantly decreases primary tumor progression, reduces metastasis, and improves survival by CD8+ T-cell–dependent mechanisms, thus indicating that the immune microenvironment of tumors can be reprogrammed to instead foster antitumor immunity and improve response to cytotoxic therapy. Cancer Discovery; 1(1); 54–67. ©2011 AACR.
This article is highlighted in the In This Issue feature, p. 4
Từ khóa
Tài liệu tham khảo
Pollard, 2009, Trophic macrophages in development and disease, Nat Rev Immunol, 9, 259, 10.1038/nri2528
Qian, 2010, Macrophage diversity enhances tumor progression and metastasis, Cell, 141, 39, 10.1016/j.cell.2010.03.014
Tang, 1992, M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes?, J Cell Biochem, 50, 350, 10.1002/jcb.240500403
Wei, 2010, Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells, J Leukoc Biol, 88, 495, 10.1189/jlb.1209822
Campbell, 2010, Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome, Breast Cancer Res Treat
Steidl, 2010, Tumor-associated macrophages and survival in classic Hodgkin's lymphoma, N Engl J Med, 362, 875, 10.1056/NEJMoa0905680
Sharma, 2010, Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ, Breast Cancer Res Treat, 123, 397, 10.1007/s10549-009-0654-0
Espinosa, 2009, Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma, Am J Pathol, 174, 2347, 10.2353/ajpath.2009.081037
Beck, 2009, The macrophage colony-stimulating factor 1 response signature in breast carcinoma, Clin Cancer Res, 15, 778, 10.1158/1078-0432.CCR-08-1283
de Visser, 2005, De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent, Cancer Cell, 7, 411, 10.1016/j.ccr.2005.04.014
DeNardo, 2009, CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages, Cancer Cell, 16, 91, 10.1016/j.ccr.2009.06.018
Andreu, 2010, FcRgamma activation regulates inflammation-associated squamous carcinogenesis, Cancer Cell, 17, 121, 10.1016/j.ccr.2009.12.019
Ammirante, 2010, B-cell-derived lymphotoxin promotes castration-resistant prostate cancer, Nature, 464, 302, 10.1038/nature08782
Guy, 1992, Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease, Mol Cell Biol, 12, 954
Lin, 2001, Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy, J Exp Med, 193, 727, 10.1084/jem.193.6.727
Breiman, 1984, Classification and regression trees. Pacific Grove, (CA): Wadsworth and Brooks/Cole Advanced Books and Software
DeNardo, 2010, Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity, Cancer Metastasis Rev, 29, 309, 10.1007/s10555-010-9223-6
Gabrilovich, 2009, Myeloid-derived suppressor cells as regulators of the immune system, Nat Rev Immunol, 9, 162, 10.1038/nri2506
Haile, 2010, CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice, J Immunol, 185, 203, 10.4049/jimmunol.0903573
Artis
Lin, 2003, Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases, Am J Pathol, 163, 2113, 10.1016/S0002-9440(10)63568-7
Lin, 2006, Macrophages regulate the angiogenic switch in a mouse model of breast cancer, Cancer Res, 66, 11238, 10.1158/0008-5472.CAN-06-1278
Lin, 2007, Tumor-associated macrophages press the angiogenic switch in breast cancer, Cancer Res, 67, 5064, 10.1158/0008-5472.CAN-07-0912
Lin, 2007, VEGF testores delayed tumor progression in tumors depleted of macrophages, Mol Oncol, 1, 288, 10.1016/j.molonc.2007.10.003
Stockmann, 2008, Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis, Nature, 456, 814, 10.1038/nature07445
Hess, 2006, Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer, J Clin Oncol, 24, 4236, 10.1200/JCO.2006.05.6861
Tabchy, 2010, Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer, Clin Cancer Res, 16, 5351, 10.1158/1078-0432.CCR-10-1265
Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 98, 10869, 10.1073/pnas.191367098
Sorlie, 2003, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A, 100, 8418, 10.1073/pnas.0932692100
Kohrt, 2005, Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer, PLoS Med, 2, e284, 10.1371/journal.pmed.0020284
Finak, 2008, Stromal gene expression predicts clinical outcome in breast cancer, Nat Med, 14, 518, 10.1038/nm1764
Leek, 1996, Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma, Cancer Res, 56, 4625
Patsialou, 2009, Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor, Cancer Res, 69, 9498, 10.1158/0008-5472.CAN-09-1868
Nowicki, 1996, Impaired tumor growth in colony-stimulating factor 1 (CSF-1)–deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1–dependent macrophages in formation of tumor stroma, Int J Cancer, 65, 112, 10.1002/(SICI)1097-0215(19960103)65:1<112::AID-IJC19>3.0.CO;2-I
Qian, 2009, A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth, PLoS One, 4, e6562, 10.1371/journal.pone.0006562
Manthey, 2009, JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia, Mol Cancer Ther, 8, 3151, 10.1158/1535-7163.MCT-09-0255
Doedens, 2010, Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression, Cancer Res, 70, 7465, 10.1158/0008-5472.CAN-10-1439
Wyckoff, 2004, A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors, Cancer Res, 64, 7022, 10.1158/0008-5472.CAN-04-1449
Serafini, 2006, Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression, Semin Cancer Biol, 16, 53, 10.1016/j.semcancer.2005.07.005
Bunt, 2007, Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression, Cancer Res, 67, 10019, 10.1158/0008-5472.CAN-07-2354
Zhang, 2010, CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis, Cytokine Growth Factor Rev, 21, 41, 10.1016/j.cytogfr.2009.11.009
Ruffell, 2010, Lymphocytes in cancer development: polarization towards pro-tumor immunity, Cytokine Growth Factor Rev, 21, 3, 10.1016/j.cytogfr.2009.11.002
Kawai, 2008, Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer, Cancer, 113, 1387, 10.1002/cncr.23712
Mantovani, 2009, Orchestration of macrophage polarization, Blood, 114, 3135, 10.1182/blood-2009-07-231795
Ma, 2010, The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time, BMC Cancer, 10, 112, 10.1186/1471-2407-10-112
Ohri, 2009, Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival, Eur Respir J, 33, 118, 10.1183/09031936.00065708
Bronkhorst, 2011, Detection of M2 macrophages in uveal melanoma and relation with survival, Invest Ophthalmol Vis Sci, 52, 643, 10.1167/iovs.10-5979
Kurahara, 2009, Significance of M2-polarized tumor-associated macrophage in pancreatic cancer, J Surg Res
Rolny, 2011, HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF, Cancer Cell, 19, 31, 10.1016/j.ccr.2010.11.009
Twelves, 2010, Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer, Clin Breast Cancer, 10, 160, 10.3816/CBC.2010.n.023
Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113
Zitvogel, 2008, The dilemma of anticancer therapy: tumor-specific versus immune effects, Blood, 112, 4364, 10.1182/blood-2008-09-176693
Brennan, 2008, Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer, Clin Cancer Res, 14, 2681, 10.1158/1078-0432.CCR-07-1760
Paulsson, 2009, Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer, Am J Pathol, 175, 334, 10.2353/ajpath.2009.081030
Rexhepaj, 2008, Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer, Breast Cancer Res, 10, R89, 10.1186/bcr2187
Mazouni, 2007, Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome, J Clin Oncol, 25, 2650, 10.1200/JCO.2006.08.2271
Moody, 2005, The transcriptional repressor Snail promotes mammary tumor recurrence, Cancer Cell, 8, 197, 10.1016/j.ccr.2005.07.009
Gene Expression Omnibus [database on the Internet]
Department of Bioinformatics and Computational Biology [database on the Internet]
Tsai, 2008, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, Proc Natl Acad Sci U S A, 105, 3041, 10.1073/pnas.0711741105